1. Search Result
Search Result
Results for "

calcium-activated

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

1

Screening Libraries

5

Peptides

5

Natural
Products

6

Recombinant Proteins

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108579

    Potassium Channel Cardiovascular Disease
    UCL 1684 (dibromide) is a first nanomolar, non-peptidic small conductance calcium-activated potassium (SK) channel blocker. UCL 1684 (dibromide) is effective in preventing the development of atrial fibrillation due to potent atrial-selective inhibition of INa. UCL 1684 (dibromide) causes atrial-selective prolongation of ERP secondary to induction of postrepolarization refractoriness .
    UCL 1684 dibromide
  • HY-W014883

    1,12-DD; 1,12-Diamino dodecane

    Potassium Channel Metabolic Disease
    1,12-Dodecanediamine (1,12-DD) is a reversible Maxi calcium-activated potassium channel blocker. 1,12-Dodecanediamine can reduce the single-channel current amplitude, mean channel open time, and channel open probability. 1,12-Dodecanediamine is promising for research of cell electrical signal transduction mechanism .
    1,12-Dodecanediamine
  • HY-109160
    Rimtuzalcap
    1 Publications Verification

    CAD-1883

    Potassium Channel Neurological Disease
    Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA) .
    Rimtuzalcap
  • HY-13519
    TRAM-34
    20+ Cited Publications

    Potassium Channel Neurological Disease
    TRAM-34 is a highly selective blocker of intermediate-conductance calcium-activated K + channel (IKCa1) (Kd=20 nM).
    TRAM-34
  • HY-100611
    CaCCinh-A01
    5+ Cited Publications

    Chloride Channel Inflammation/Immunology Cancer
    CaCCinh-A01 is an inhibitor of both TMEM16A and calcium-activated chloride channel (CaCC) with IC50s of 2.1 and 10 μM, respectively.
    CaCCinh-A01
  • HY-N5101
    Kobusin
    1 Publications Verification

    CFTR Chloride Channel Neurological Disease Inflammation/Immunology
    Kobusin is a bisepoxylignan isolated from the Pnonobio biondii Pamp. Kobusin is an activator of CFTR and CaCCgie chloride channels and a inhibitor of ANO1/CaCC (calcium-activated chloride channel) channel .
    Kobusin
  • HY-107301

    Soyasaponin Be; DHS-I

    Potassium Channel Neurological Disease
    Dehydrosoyasaponin I (Soyasaponin Be;DHS-I), a triterpene glycoside, is a potent and reversible calcium-activated potassium (maxi-K) channels activator .
    Dehydrosoyasaponin I
  • HY-176856

    Potassium Channel Neurological Disease
    Maxi-K modulator 1 (Example 1) is a Maximum conductance calcium-activated potassium (Maxi-K) channel modulator. Maxi-K modulator 1 has a potent stimulating effect on Maxi-K channel activity. Maxi-K modulator 1 can be used for fragile X syndrome research .
    Maxi-K modulator 1
  • HY-122104

    Potassium Channel Neurological Disease
    UCL-1848 TFA is a hSK1 blocker with an IC50 value of 1.1 nM. hSK1 is a small conductance calcium-activated potassium channel .
    UCL-1848 TFA
  • HY-P3111

    Potassium Channel Others
    Slotoxin, a peptide from Centruroides noxius Hoffmann scorpion venom, blocks high conductance calcium-activated potassium channel, with Kd of 1.5 nM[1].
    Slotoxin
  • HY-146334

    Chloride Channel Inflammation/Immunology
    DFBTA is an orally active, potent and little brain penetrated ANO1 (Calcium-activated chloride channel anoctamin-1) inhibitor, with an IC50 of 24 nM. DFBTA shows analgesic efficacy for inflammatory pain .
    DFBTA
  • HY-P1281

    Potassium Channel Neurological Disease
    Kaliotoxin is a peptidyl inhibitor of neuronal BK-Type. Kaliotoxin can specific inhibit Kv channels and calcium-activated potassium channels. Kaliotoxin can be used for the research of the regulation of membrane potential and neuron excitability .
    Kaliotoxin
  • HY-P2710

    Potassium Channel Neurological Disease Inflammation/Immunology
    Noxiustoxin is a toxin from the venom of the Mexican scorpion Centruroides noxius which block voltage-dependent potassium channel (Kv1.3, IC50 = 360 nM), and calcium-activated potassium channel. Noxiustoxin plays an important role in neuroinflammatory disease .
    Noxiustoxin
  • HY-100227
    E 64c
    2 Publications Verification

    Cathepsin SARS-CoV Metabolic Disease
    E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.
    E 64c
  • HY-108772

    Provir; SP 303

    CFTR Chloride Channel Others
    Crofelemer (Provir) is an orally active antidiarrheal agent. Crofelemer acts on the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CACC) , which are responsible for chloride and fluid secretion in the gastrointestinal tract. Crofelemer can be used in the research of diarrheal diseases .
    Crofelemer
  • HY-100612
    T16Ainh-A01
    2 Publications Verification

    Chloride Channel Others
    T16Ainh-A01, an aminophenylthiazole, is a potent transmembrane protein 16A (TMEM16A) inhibitor, inhibiting TMEM16A-mediated chloride currents with an IC50 value of ~1 µM. TMEM16A (ANO1) functions as a calcium-activated chloride channel (CaCC) .
    T16Ainh-A01
  • HY-B0252
    Hydrochlorothiazide
    5 Publications Verification

    HCTZ

    TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease Cancer
    Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide
  • HY-W703190

    Inositol 1,4,5,6-tetraphosphate; D-Ins(1,4,5,6)P4

    Endogenous Metabolite Metabolic Disease
    D-myo-Inositol-1,4,5,6-tetraphosphate (D-Ins(1,4,5,6)P4) is one of several different inositol oligophosphate isomers implicated in signal transduction. It almost completely inhibits calcium-activated chloride channels at a concentration of 8-10 μM .
    D-myo-Inositol-1,4,5,6-tetraphosphate
  • HY-118628
    (E/Z)-BML264
    5+ Cited Publications

    N-(p-Amylcinnamoyl) anthranilic acid; ACA

    Phospholipase TRP Channel Cardiovascular Disease
    (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A2 (PLA2) inhibitor and TRP channel blocker . (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia .
    (E/Z)-BML264
  • HY-B0252S

    HCTZ-d2

    TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease
    Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazid-d2
  • HY-18723
    Yoda 1
    Maximum Cited Publications
    79 Publications Verification

    Piezo Channel Akt ERK Potassium Channel Cardiovascular Disease
    Yoda 1 is a potent and selective Piezo1 agonist. Yoda 1 activates purified Piezo1 channels. Yoda 1 potently inhibits macropinocytosis induced by epidermal growth factor (EGF). Yoda 1 enhances Ca 2+ influx followed by activation of the calcium-activated potassium channel KCa3.1 and inhibition of Rac1 activation .
    Yoda 1
  • HY-120355

    Potassium Channel Cardiovascular Disease
    AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits KCa2.2 channel and KCa channel with IC50 of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect .
    AP14145
  • HY-B0252R
    Hydrochlorothiazide (Standard)
    5 Publications Verification

    HCTZ (Standard)

    Reference Standards TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease Cancer
    Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide (Standard)
  • HY-B0252S2

    HCTZ-13C6

    TGF-beta/Smad Potassium Channel Metabolic Disease
    Hydrochlorothiazide- 13C6 is the 13C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide-13C6
  • HY-102070

    Potassium Channel Neurological Disease
    NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias .
    NS13001
  • HY-B0252S1

    HCTZ-13C,d2

    Isotope-Labeled Compounds TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease
    Hydrochlorothiazid- 13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazid-13C,d2
  • HY-153508

    Chloride Channel Others
    ANO1-IN-4 (Compound 10bm) is a reversible inhibitor for calcium-activated chloride channel transmembrane protein 16A (TMEM16A, also known as ANO1) with an IC50 of 0.030 µM. ANO1-IN-4 exhibits good metabolic stability in rat liver microsomes. ANO1-IN-4 inhibits spontaneous contraction in mouse isolated ileum .
    ANO1-IN-4
  • HY-170918

    Potassium Channel Others
    BKCa activator-1 (Compound 51b) is the orally active activator for the calcium-activated potassium channel BKCa with an EC50 of 2.82 μM. BKCa activator-1 increases K+ efflux, leads to cell membrane hyperpolarization, thereby inhibiting smooth muscle contraction. BKCa activator-1 alleviates urinary incontinence in spontaneously hypertensive rat (SHR) model, exhibits antitussive effect in puinea pig cough model .
    BKCa activator-1
  • HY-108584

    BMS-204352

    Potassium Channel Neurological Disease
    Flindokalner (BMS-204352) is a potassium channel modulator. Flindokalner is a positive modulator of all neuronal Kv7 channel subtypes expressed in HEK293 cells. Flindokalner is also a large conductance calcium-activated K channel (BKca) positive modulator. Flindokalner shows a negative modulatory activity at Kv7.1 channels (Ki=3.7 μM), and acts as a negative modulator of GABAA receptors. Flindokalner shows anxiolytic efficacy in vivo .
    Flindokalner
  • HY-B0493
    Niflumic acid
    2 Publications Verification

    Chloride Channel COX Inflammation/Immunology Cancer
    Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .
    Niflumic acid
  • HY-B0252S3

    HCTZ-15N2,13C,d2

    Potassium Channel TGF-beta/Smad Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease Cancer
    Hydrochlorothiazide- 15N2, 13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide-15N2,13C,d2
  • HY-102052

    Potassium Channel Metabolic Disease
    DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia .
    DCEBIO
  • HY-108584R

    Potassium Channel Neurological Disease
    Flindokalner (Standard) is the analytical standard of Flindokalner. This product is intended for research and analytical applications. Flindokalner (BMS-204352) is a potassium channel modulator. Flindokalner is a positive modulator of all neuronal Kv7 channel subtypes expressed in HEK293 cells. Flindokalner is also a large conductance calcium-activated K channel (BKca) positive modulator. Flindokalner shows a negative modulatory activity at Kv7.1 channels (Ki=3.7 μM), and acts as a negative modulator of GABAA receptors. Flindokalner shows anxiolytic efficacy in vivo .
    Flindokalner (Standard)
  • HY-120059

    Potassium Channel Neurological Disease
    NS4591 is a modulator of calcium-activated potassium channels with activity that enhances small (SK) and intermediate (IK) conductivity. NS4591 doubled IK-mediated currents in whole-cell patch-clamp experiments at a concentration of 45 +/- 6 nM, and doubled SK3-mediated currents at a concentration of 530 +/- 100 nM. NS4591 inhibits the number of action potentials generated by suprathreshold depolarizing pulses in acutely isolated bladder primary afferent neurons. NS4591 also reduced carbakol-induced detrusor ring contraction in the rat bladder, demonstrating sensitivity to apamin .
    NS4591
  • HY-B0493R

    Reference Standards Chloride Channel COX Inflammation/Immunology
    Niflumic acid (Standard) is the analytical standard of Niflumic acid. This product is intended for research and analytical applications. Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .
    Niflumic acid (Standard)
  • HY-Y0095

    2-Hydroxyethanesulfonic acid

    Mitochondrial Metabolism Parasite Metabolic Disease
    Isethionic acid is a calcium binder and anionic detergent that enhances mitochondrial calcium binding capacity by competitively binding to calcium binding sites on the outer mitochondrial membrane. Isethionic acid can inhibit calcium-activated mitochondrial respiration. Isethionic acid inhibits barnacle (Balanus amphitrite) larvae with LC50s of 23 μg/mL (24 h) and 17 μg/mL (48 h), respectively. Isethionic acid can inhibit the attachment of barnacle larvae (complete inhibition at 10 μg/mL) and regulate mitochondrial calcium transport, and can enhance ATP-dependent calcium uptake at high calcium concentrations. Isethionic acid can be used to study the mechanism of mitochondrial calcium metabolism.
    Isethionic acid (80% in water)
  • HY-B1371A
    Spiperone hydrochloride
    2 Publications Verification

    Spiroperidol hydrochloride

    Dopamine Receptor 5-HT Receptor Adrenergic Receptor Chloride Channel Neurological Disease Inflammation/Immunology
    Spiperone hydrochloride (Spiroperidol hydrochloride) is a selective dopamine D2 receptor (Ki values of 0.06 nM, 0.6 nM, 0.08 nM, ~350 nM, ~3500 nM for D2, D3, D4, D1 and D5 receptors, respectively) and 5-HT2A/5-HT1A receptor (Kis of 1 nM/49 nM) antagonist. Spiperone hydrochloride is also a selective α1B-adrenoceptor antagonist. Spiperone hydrochloride activates calcium-activated chloride channel (CaCC). Antipsychotic and anti-inflammatory activities .
    Spiperone hydrochloride
  • HY-175387

    Ins(1,3,4)-P3 sodium; 1,3,4-IP3 sodium

    Endogenous Metabolite Others
    D-myo-Inositol-1,3,4-triphosphate (sodium) is one of the inositol oligophosphate isomers implicated in signal transduction. D-myo-Inositol-1,3,4-triphosphate (sodium) acts through the inhibition of Ins(3,4,5,6)-P4 kinase activity to increase cellular level of Ins(3,4,5,6)-P4, thereby inhibiting calcium-activated chloride channels. D-myo-Inositol-1,3,4-triphosphate (sodium) can be regulated by the levels of cytosolic free calcium .
    D-myo-Inositol-1,3,4-triphosphate sodium
  • HY-N3463

    Potassium Channel Neurological Disease
    Isopimaric acid is a potent opener of large conductance calcium activated K + (BK) channels.
    Isopimaric acid
  • HY-P4121

    Potassium Channel Inflammation/Immunology Cancer
    L17E is an attenuated cationic amphiphilic lytic (ACAL) peptide that can be used to deliver a variety of macromolecules, including proteins, antibodies, and DNA nanostructures. L17E inserts and cleaves the membrane structure through electrostatic interaction, enabling intracellular escape. The efficiency of L17E-mediated delivery is strongly correlated with the expression level of KCNN4 (the gene encoding the calcium-activated potassium channel KCa3.1). L17E also promotes the cellular uptake of macromolecules by inducing micropinocytosis. L17E can be further optimized and improved through dimerization strategies and in combination with other delivery systems, such as nuclear localization signal peptides and cell membrane-coated nanoparticles .
    L17E
  • HY-B0380A

    Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
    Trimebutine maleate
  • HY-B0380

    Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
    Trimebutine
  • HY-B0380S2

    Isotope-Labeled Compounds Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Trimebutine-d3 hydrochloride is deuterium labeled Trimebutine hydrochloride. Trimebutine hydrochloride is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine hydrochloride inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine hydrochloride also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine hydrochloride also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine hydrochloride also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
    Trimebutine-d3 hydrochloride
  • HY-B0380S1

    Isotope-Labeled Compounds Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Trimebutine-d5 fumarate is deuterium labeled Trimebutine fumarate. Trimebutine fumarate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine fumarate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine fumarate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine fumarate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine fumarate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
    Trimebutine-d5 fumarate
  • HY-B0380AR

    Reference Standards Opioid Receptor Apoptosis Potassium Channel NF-κB Akt IRAK JNK Toll-like Receptor (TLR) ERK Calcium Channel Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Trimebutine maleate (Standard) is the analytical standard of Trimebutine maleate (HY-B0380A). This product is intended for research and analytical applications. Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
    Trimebutine maleate (Standard)
  • HY-B0380R

    Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Trimebutine (Standard) is the analytical standard of Trimebutine (HY-B0380). This product is intended for research and analytical applications. Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
    Trimebutine (Standard)
  • HY-13103
    NS 11021
    3 Publications Verification

    Potassium Channel Others
    NS 11021 is a potent and specific Ca 2+-activated big-conductance K + Channels (KCa1.1 channels) activator. NS 11021 at concentrations above 0.3 μM activates KCa1.1 in a concentration-dependent manner by parallelshifting the channel activation curves to more negative potentials .
    NS 11021
  • HY-122605

    CBA

    TRP Channel Cardiovascular Disease Cancer
    TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC50 of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer .
    TRPM4-IN-1
  • HY-P2791

    Potassium Channel Neurological Disease Inflammation/Immunology
    Tertiapin (reduced) is a kind of synthesis of melittin, its Cys3-Cys14 and Cys5-Cys18 between containing a disulfide bond. Tertiapin (reduced) is a kind of inward rectifier potassium channels blockers, can block the activity of calcium activates large conductance potassium channels. Tertiapin (reduced) can be used for research in diseases such as rheumatoid arthritis and multiple sclerosis .
    Tertiapin (reduced)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: